FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 32350104

Estimated average burden
hours per
response: 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Ali Faraz	Requiring (Month/Da	2. Date of Event Requiring Statement (Month/Day/Year) 07/29/2021 3. Issuer Name and Ticker or Trading Symbol Tenaya Therapeutics, Inc. [TNYA]						
(Last) (First) (Middle) C/O TENAYA THERAPEUTICS, INC.			4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner			5. If Amendment, Date of Original Filed (Month/Day/Year)		
171 OYSTER POINT BLVD., 5TH FLR.	_		X Officer (give title below) Chief Executive	Other (below) ve Officer	specify		ck Applicable Form filed b	nt/Group Filing Line) by One Reporting
(Street) SOUTH SAN FRANCISCO CA 94080							Person Form filed to Reporting F	by More than One Person
(City) (State) (Zip)								
Table I - Non-Derivative Securities Beneficially Owned								
1. Title of Security (Instr. 4)			2. Amount of Securities Beneficially Owned (Instr. 4)	3. Owne Form: D (D) or In (I) (Instr	Direct Own		ature of Indirect Beneficial Iership (Instr. 5)	
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)								
'	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Convers	sion (Form:	6. Nature of Indirect Beneficial Ownership (Instr.
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security		Direct (D) or Indirect (I) (Instr. 5)	5)
Stock Option (Right to buy)	(1)	09/06/2028	Common Stock	425,000	0.66	5	D	
Stock Option (Right to buy)	(2)	03/10/2030	Common Stock	41,666	2.7		D	
Stock Option (Right to buy)	(3)	02/27/2031	Common Stock	416,666	5.64	1	D	
Stock Option (Right to buy)	(4)	06/17/2031	Common Stock	166,666	9.36	5	D	

Explanation of Responses:

- 1. 1/5th of the shares subject to the option granted on September 6, 2018 became vested and exercisable as of June 27, 2019 and 1/60th of the shares subject to the option shall vest monthly thereafter, provided that the Reporting Person remains a service provider to the issuer on each such vest date.
- 2. 1/48th of the shares subject to the option granted on March 10, 2020 became vested and exercisable as of April 10, 2020 and 1/48th of the shares subject to the option shall vest monthly thereafter, provided that the Reporting Person remains a service provider to the issuer on each such vest date.
- 3. 1/48th of the shares subject to the option granted on February 27, 2021 became vested and exercisable as of March 27, 2021 and 1/48th of the shares subject to the option shall vest monthly thereafter, provided that the Reporting Person remains a service provider to the issuer on each such vest date.
- 4. 1/48th of the shares subject to the option granted on June 17, 2021 became vested and exercisable as of July 17, 2021 and 1/48th of the shares subject to the option shall vest monthly thereafter, provided that the Reporting Person remains a service provider to the issuer on each such vest date.

Remarks:

Date set forth above represents the effective date of the Issuer's initial public offering.

/s/Leone Patterson
Attorney-in-Fact for Faraz 07/29/2021
Ali

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

The undersigned, as a Section 16 reporting person of Tenaya Therapeutics, Inc. (the Company), hereby constitutes and appoints Faraz Ali and Leone Patterson, and each of them, as the true and lawful attorney-in-fact of the undersigned to:

- 1. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the ownership, acquisition or disposition of securities of the Company by the undersigned; and
- 2. do all acts necessary in order to file such forms with the SEC, any securities exchange or national association, the Company and such other person or agency as the attorneys-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the responsibilities of the undersigned to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the holdings of and transactions of the undersigned in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 7th day of July, 2021.

Signature:/s/Faraz Ali

Print Name: Faraz Ali